Invest in a Prescription Medicine Breakthrough

From the co-inventor of the Listerine strip, we’re using the same oral film technology to make medicine easier to absorb, working towards helping treat migraines, Alzheimer’s, and more.

Invest now
Min. Investment
Share Price

Top 3 Reasons to Invest in IntelGenx

1Strong Pipeline

Over 80 Issued and Pending Patents

in our pipeline

2Quarterly Dividend

8% Dividend

Preferred Stock

An exclusive opportunity for you to earn a dividend.

3Massive Potential Market

$510B Market1

Pharmaceutical Industry

We see significant potential demand across pharma markets including Erectile Dysfunction, Alzheimer’s, and Parkinson’s Disease.


Up to 40% of Adults Reportedly Have TROUBLE Swallowing Pills

Whether due to age, medical conditions, or personal discomfort, as many as 40% of adults have trouble swallowing tablets. Without an alternative, it could be difficult for them to access important medications that they need.


The Pill Alternative of the Future

Our oral film technology both increases drug absorption and reduces side effects. We’re striving to make essential medications more accessible to everyone, ensuring that no one is left struggling with pill swallowing issues.


Rapidly disintegrating, no need for water, easy to carry and to administer, discreet


Fast disintegration, increased drug absorption across mucosa leading to high bioavailability, faster onset of action, reduced side effects


Intimate and prolonged contact with the mucosa, improved drug permeation reducing first-pass metabolism, limited stomach exposure


Minimally invasive and painless approach compared to injection, avoidance of first-pass drug metabolism, reduced dosing frequency

We’re Already FDA-Approved for migraines

Strong Industry Collaborations

We’ve established pivotal partnerships with leading drug companies and cannabis industry players.

State-of-the-Art Manufacturing Facility

We've invested in a large and fully compliant facility, certified by both the FDA and Health Canada.

Versafilm: A Milestone in the Making

Exciting times lie ahead as we prepare for the launch of our first commercial product, Versafilm, scheduled for Q2 2024.

Get the Investor Deck

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our Pipeline to Pharma Success


FDA-approved pharmaceutical film for migraines.

Mild to moderate Alzheimer's treatment, currently in Phase II clinical trials.
Cannabis CBD & THC

Already launched and introduced into the cannabis market.
N-Dimethyltryptamine (DMT)
In development, exploring new frontiers in pharmaceuticals.
VetaFilm (for animals)

In development, working to offer innovative solutions for veterinary care.

Earn An 8% Dividend on IGXT Stock

Purchasing and holding preferred stock through this offering provides the opportunity to share in our projected growth with a $0.20 per share quarterly dividend. Plus, after 6 months, your preferred shares can be converted into common stock.

Working to Unlock the Pharma Market

Working towards capturing an increasing share of pharmaceutical market, we’ve developed drugs that target a range of therapeutic areas, including:

Get the Investor Deck

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Invest in a Team with Decades of Pharma Expertise

Dwight Gorham, CEO
30+ years CMO experience in pharma
Andre Godin, President & CFO
25+ years biotech/pharma industry experience
Nadine Paiement, VP, R&D
20 years experience in product development and tech transfer


What is your preferred share price?


What is the minimum investment amount?


What kind of shares are you issuing?

Series A Convertible Cumulative Preferred Shares

Redemption Feature
Commencing on the fifth anniversary of the initial closing of this offering and continuingindefinitely thereafter, we shall have a right to call for redemption the outstanding shares of our Series A Preferred Stock at a call price equal to 150% of the original issue price of our Series A Preferred Stock, and correspondingly, each holder of shares of our Series A Preferred Stock shall have a right to put the shares of Series A Preferred Stock held by such holder back to us at a put price equal to 150% of the original issue purchase price of such shares. The Series A Preferred Stock will have no voting rights (except for certain limited matters described further in the offering circular).

Conversion Feature

Each share of the Series A Preferred Stock is convertible into twenty (20) shares of our Common Stock at the option of the holder. Our common shares trade on the TSX: IGX and OTCQB:IGXT

How much are you raising?

Up to $20M

What is the current coupon?

Holders of our Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter which is an 8% rate.

How do you plan to use the proceeds from this funding round?

New product launches, working capital and debt repayment.

How will I get a return on my investment?

Holders of our Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter, which is equivalent to the annual rate of 8.00% of the $10.00 purchase price per share; provided that upon an event of default (generally defined as our failure to pay dividends when due or to redeem shares when requested by a holder), such amount shall be increased to $0.30 per quarter, which is equivalent to the annual rate of 12% of the $10.00 purchase price per share.

Each holder of the Series A Preferred Stock is entitled to convert any of the outstanding shares of Series A Preferred Stock held by such holder into validly issued, fully paid and non-assessable shares of our Common Stock. Each share of the Series A Preferred Stock is convertible into our Common Stock at the conversion rate of 1 share of Series A Preferred Stock to 20 shares of Common Stock, subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock.

In certain exit opportunities you could convert your shares into cash or a more liquid asset. Exits include getting acquired by a larger company, or our company buying back shares. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by IntelGenx are highly speculative. Investing in shares of IntelGenx involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

IntelGenx intends to list the Preferred Stock offered under this Form 1-A on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.

 When will I receive my shares?

Shares will be allocated after the investment funds clear. This typically takes around 3weeks after investment which shall be held directly with our transfer agent Pacific StockTransfer Company, 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119, Tel. 702-361-3033.

Are there higher fees if you invest via credit card vs. ACH?

No, costs are the same, regardless of how you invest

How do I know people will buy this solution?

Although there is no guarantee that the market will be receptive to products incorporating our drug delivery technologies, the company has demonstrated considerable traction, reassuring investors of its market potential. They have forged strategic partnerships with major players in the pharmaceutical and cannabis industries, like atai Life Sciences and Gensco Pharma, lending credibility and market access. A pivotal achievement is the FDA approval of their migraine product, Rizafilm, a testament to the product's efficacy and safety. Their state-of-the-art manufacturing facility is ready to meet large-scale production demands, vital for market supply. With a diverse range of products targeting substantial markets such as migraines, erectile dysfunction, Pain, Alzheimer's, and Parkinson's diseases, the company diversifies its market risk. Additionally, initial purchase orders from companies like Tilray for their cannabis products indicate immediate market interest, and plans to start commercial sales of Versafilm in 2024 further underscore their market readiness and potential for revenue growth. These elements collectively offer investors a clear picture of the company's strong market position and promising future sales prospects.

Are there more opportunities ahead?

We believe that the growth potential for this company is promising and the company may be positioned to expand their market reach significantly, thanks to their innovative thin film technology and a diverse product range targeting key health areas. Their active development pipeline, focused on conditions like Alzheimer's, Parkinson's, Animal Health and applications in cannabis, signals ongoing innovation and relevance in the pharmaceutical industry. Strategic partnerships with major players could offer immediate market access and potential for future expansion. The company's success in securing FDA approval showcases their ability to navigate global regulatory landscapes, opening doors to international markets. Additionally, the rising demand for user-friendly drug delivery systems, coupled with their ability to repurpose well-known drugs for new uses, should offer a faster route to market expansion. Additionally, we believe their robust manufacturing and distribution capabilities should help them meet any increasing demand efficiently. All these factors combined suggest a strong trajectory for potential growth and expansion in the coming years.

 Why should I invest?

Investing in this company may offer a unique opportunity to be part of a potential pioneering shift in pharmaceuticals. Their cutting-edge thin film technology can simplify medication intake, making it easier, faster, and more efficient than many traditional methods. We believe this innovation is not just a step forward in patient convenience and compliance but also enhances the effectiveness of medications. The company's diverse portfolio, including successful ventures into the growing markets of migraines, erectile dysfunction, Pain, Alzheimer's, and Parkinson's disease treatments, as well as cannabis, indicates a broad and scalable application of their technology. Additionally, the company's solid partnerships with established pharmaceutical and cannabis companies, recent FDA approvals, and a robust pipeline of products in various stages of development and commercialization could further solidify its investment potential. We believe this combination of innovative technology, strategic partnerships, and market-ready solutions positions the company as an attractive investment opportunity in a lucrative pharmaceutical industry.

Why didn't a bigger company do this already?

IntelGenx has a strong R&D program, including the creator of the Listerine strip on their side. We believe this would be cost intensive for another company to replicate and gives them a first-mover advantage.

What development services does IntelGenx offer?

IntelGenx offers a comprehensive range of development services covering the entire product lifecycle of drug development. These include formulation prototype development, technology transfer, process scale-up, regulatory support, and clinical studies monitoring.

 What analytical testing services does IntelGenx offer?

IntelGenx provides third-party analytical testing services, including method development and validation, release and in-process testing, and ICH stability storage and testing.

What is the nature of the partnership between IntelGenx and atai?

IntelGenx has entered into an exclusive partnership with atai to develop compounds for the prevention or treatment of mental health diseases or disorders. This collaboration encompasses compounds with psychedelic, entactogenic, and/or oneirophrenic properties.

Join the Discussion

Loading Comments